Arena Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing novel drugs for weight management, cardiovascular disease, inflammation and other disorders.
In June 2012, the US Food and Drug Administration (FDA) approved our internally discovered and developed drug, BELVIQ® (lorcaserin HCl). Following are links to certain additional information:
The US Food and Drug Administration approved BELVIQ and recommended it for scheduling by the Drug Enforcement Administration. BELVIQ will be available only after scheduling is effective. BELVIQ has not been approved by any other regulatory agency.
BELVIQ is currently under review for marketing approval in the European Union and Switzerland, and we intend to seek regulatory approval in additional territories. Regulatory agencies outside of the US will independently review BELVIQ.
We have granted exclusive marketing and distribution rights to Eisai Inc. for most of North and South America, and to Ildong Pharmaceutical Co., Ltd., for South Korea. We plan to enter into additional collaborations to commercialize BELVIQ outside of these territories.
Delayed at least 20 minutes. Provided by eSignal.
The stock information, SEC filings and press releases included on this website are not provided by Arena Pharmaceuticals, Inc. but by a third-party. Such information is not intended for trading purposes. Arena Pharmaceuticals, Inc. does not guarantee the accuracy or completeness of this information and is not liable in any way whatsoever for any delays, inaccuracies, errors in, or omissions of any such information, or for any actions taken in reliance on this information, or for any damages arising there from.